Riociguat isa sGC stimulator and is the only drug approved for both PAH and chronic thromboembolic pulmonary hypertension (CTEPH) (Ghofrani et al., 2013; Simonneau et al., 2015). This evidence concerns the gene SGCB and pulmonary arterial hypertension.